SSA Swiss Advisors AG Increases Stake in Novo Nordisk A/S $NVO

SSA Swiss Advisors AG grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 27.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,901 shares of the company’s stock after buying an additional 12,845 shares during the quarter. Novo Nordisk A/S accounts for 2.0% of SSA Swiss Advisors AG’s investment portfolio, making the stock its 15th largest holding. SSA Swiss Advisors AG’s holdings in Novo Nordisk A/S were worth $4,172,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Focus Partners Advisor Solutions LLC raised its position in Novo Nordisk A/S by 16.3% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 7,318 shares of the company’s stock worth $504,000 after buying an additional 1,024 shares during the last quarter. Northstar Asset Management Inc. grew its stake in shares of Novo Nordisk A/S by 14.3% during the 2nd quarter. Northstar Asset Management Inc. now owns 169,557 shares of the company’s stock worth $11,703,000 after purchasing an additional 21,181 shares during the period. LJI Wealth Management LLC grew its stake in shares of Novo Nordisk A/S by 10.8% during the 2nd quarter. LJI Wealth Management LLC now owns 5,130 shares of the company’s stock worth $354,000 after purchasing an additional 500 shares during the period. AlTi Global Inc. grew its stake in shares of Novo Nordisk A/S by 90.5% during the 2nd quarter. AlTi Global Inc. now owns 10,648 shares of the company’s stock worth $735,000 after purchasing an additional 5,059 shares during the period. Finally, 180 Wealth Advisors LLC grew its stake in shares of Novo Nordisk A/S by 9.5% during the 2nd quarter. 180 Wealth Advisors LLC now owns 5,492 shares of the company’s stock worth $379,000 after purchasing an additional 478 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on NVO. TD Cowen lowered their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 19th. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price objective on the stock in a research note on Wednesday, August 13th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $76.00.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $53.02 on Friday. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $114.19. The stock has a market capitalization of $236.74 billion, a P/E ratio of 14.57, a P/E/G ratio of 2.42 and a beta of 0.68. The firm’s 50-day moving average is $56.56 and its two-hundred day moving average is $62.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.